{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:02:00Z","timestamp":1781712120582,"version":"3.54.5"},"reference-count":203,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.heliyon.2023.e13285","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T03:18:56Z","timestamp":1675135136000},"page":"e13285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2657-9121","authenticated-orcid":false,"given":"Mohammad Shah","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5455\/javar.2020.g410","article-title":"The emergence of novel coronavirus disease (COVID-19) in Bangladesh: present status, challenges, and future management","volume":"7","author":"Alam","year":"2020","journal-title":"J. Adv. Veter. Ani. Res."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13285_bib2","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1080\/17441692.2020.1811366","article-title":"COVID-19: can this crisis be transformative for global health?","volume":"15","author":"Casale","year":"2020","journal-title":"Global Publ. Health"},{"key":"10.1016\/j.heliyon.2023.e13285_bib4","author":"Data"},{"key":"10.1016\/j.heliyon.2023.e13285_bib5","series-title":"Rapid Epidemic Expansion of the SARS-CoV-2 Omicron Variant in Southern Africa","author":"Viana","year":"2021"},{"issue":"10278","key":"10.1016\/j.heliyon.2023.e13285_bib6","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","article-title":"SARS-CoV-2 variants and ending the COVID-19 pandemic","volume":"397","author":"Fontanet","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13285_bib7","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/jmv.27516","article-title":"Sequence analysis of the emerging SARS\u2010CoV\u20102 variant Omicron in South Africa","volume":"94","author":"Wang","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.heliyon.2023.e13285_bib8","series-title":"Virological Characteristics of the SARS-CoV-2 Omicron BA. 2 Spike","author":"Yamasoba","year":"2022"},{"key":"10.1016\/j.heliyon.2023.e13285_bib9","first-page":"376","article-title":"Covid-19: what do we know about omicron sublineages?","author":"Mahase","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2023.e13285_bib10","series-title":"SARS-CoV-2 Omicron Sub-lineages BA. 4 and BA. 5","author":"Update","year":"2022"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13285_bib11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nature microbiology"},{"issue":"21","key":"10.1016\/j.heliyon.2023.e13285_bib12","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.heliyon.2023.e13285_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104792","article-title":"Coronavirus membrane fusion mechanism offers a potential target for antiviral development","volume":"178","author":"Tang","year":"2020","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib15","first-page":"1","article-title":"SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2023.e13285_bib16","first-page":"1","article-title":"The first two imported cases of SARS-CoV-2 omicron variant\u2014tianjin municipality, China, december 13, 2021","volume":"3","author":"Tan","year":"2021","journal-title":"China CDC Weekly"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/22221751.2020.1725399","article-title":"RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak","volume":"9","author":"Chen","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.heliyon.2023.e13285_bib18","series-title":"Delta Spike P681R Mutation Enhances SARS-CoV-2 Fitness over Alpha Variant","author":"Liu","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105226","article-title":"SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody","volume":"142","author":"Omotuyi","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.heliyon.2023.e13285_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.112816","article-title":"Emergence of SARS-CoV-2 Omicron (B. 1.1. 529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic","volume":"209","author":"Khandia","year":"2022","journal-title":"Environ. Res."},{"issue":"7898","key":"10.1016\/j.heliyon.2023.e13285_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e13285_bib22","series-title":"SARS-CoV-2 Omicron Spike Mediated Immune Escape, Infectivity and Cell-Cell Fusion","author":"Meng","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib23","first-page":"2013","article-title":"Variable loss of antibody potency against SARS-CoV-2 B. 1.1. 52 9 (Omicron), nuevos sist, comun","volume":"529","author":"Abarca","year":"2021","journal-title":"OR Inf."},{"issue":"7898","key":"10.1016\/j.heliyon.2023.e13285_bib24","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"10.1016\/j.heliyon.2023.e13285_bib25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"10.1016\/j.heliyon.2023.e13285_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"issue":"7902","key":"10.1016\/j.heliyon.2023.e13285_bib27","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e13285_bib28","series-title":"Structural Diversity of the SARS-CoV-2 Omicron Spike","author":"Gobeil","year":"2022"},{"issue":"6582","key":"10.1016\/j.heliyon.2023.e13285_bib29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1126\/science.abn7760","article-title":"SARS-CoV-2 Omicron variant: antibody evasion and cryo-EM structure of spike protein\u2013ACE2 complex","volume":"375","author":"Mannar","year":"2022","journal-title":"Science"},{"issue":"6583","key":"10.1016\/j.heliyon.2023.e13285_bib30","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1126\/science.abn8652","article-title":"Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement","volume":"375","author":"McCallum","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2023.e13285_bib31","series-title":"The SARS-CoV-2 Variant, Omicron, Shows Rapid Replication in Human Primary Nasal Epithelial Cultures and Efficiently Uses the Endosomal Route of Entry","first-page":"2021","author":"Peacock","year":"2022"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13285_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/molbev\/msac061","article-title":"Selection analysis identifies clusters of unusual mutational changes in Omicron lineage BA. 1 that likely impact Spike function","volume":"39","author":"Martin","year":"2022","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.heliyon.2023.e13285_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113522","article-title":"Omicron variant (B. 1.1. 529) and its sublineages: what do we know so far amid the emergence of recombinant variants of SARS-CoV-2?","author":"Dhawan","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2023.e13285_bib34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bj.2022.04.006","article-title":"SARS-CoV-2 variants\u2013evolution, spike protein, and vaccines","volume":"45","author":"Chen","year":"2022","journal-title":"Biomed. J."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13285_bib35","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13285_bib36","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"issue":"7857","key":"10.1016\/j.heliyon.2023.e13285_bib37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e13285_bib38","series-title":"Spike Protein Cleavage-Activation Mediated by the SARS-CoV-2 P681R Mutation: a Case-Study from its First Appearance in Variant of Interest (VOI) A. 23.1 Identified in Uganda","author":"Lubinski","year":"2021"},{"issue":"7849","key":"10.1016\/j.heliyon.2023.e13285_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-021-03237-4","article-title":"Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis","volume":"591","author":"Johnson","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e13285_bib40","article-title":"Analysis of SARS-COV2 spike protein variants among Iraqi isolates","volume":"26","author":"Sabir","year":"2022","journal-title":"Gene Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cmi.2021.09.007","article-title":"Monitoring the SARS-CoV-2 pandemic: screening algorithm with single nucleotide polymorphism detection for the rapid identification of established and emerging variants","volume":"28","author":"Mertens","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"issue":"6599","key":"10.1016\/j.heliyon.2023.e13285_bib42","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1126\/science.abm1208","article-title":"Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness","volume":"376","author":"Obermeyer","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2023.e13285_bib43","article-title":"Convalescent plasma therapy against the emerging SARS-CoV-2 variants: delineation of the potentialities and risks","author":"Dhawan","year":"2021","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.heliyon.2023.e13285_bib44","article-title":"Emergence of omicron variant's sublineages BA. 4 and BA. 5: risks assessment and possible countermeasures","volume":"48","author":"Dhawan","year":"2022","journal-title":"New Microb. New Inf."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13285_bib45","article-title":"The latest Omicron BA. 4 and BA. 5 lineages are frowning toward COVID\u201019 preventive measures: a threat to global public health","volume":"5","author":"Islam","year":"2022","journal-title":"Heal. Sci. Rep."},{"issue":"10317","key":"10.1016\/j.heliyon.2023.e13285_bib46","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-022-02312-5","article-title":"Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant","volume":"20","author":"Schubert","year":"2022","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib48","first-page":"1","article-title":"Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection","volume":"13","author":"Zou","year":"2022","journal-title":"Nat. Commun."},{"issue":"6620","key":"10.1016\/j.heliyon.2023.e13285_bib49","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1126\/science.adc9127","article-title":"Imprinted antibody responses against SARS-CoV-2 Omicron sublineages","volume":"378","author":"Park","year":"2022","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.heliyon.2023.e13285_bib50","article-title":"Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France","volume":"27","author":"Castillo","year":"2022","journal-title":"Euro Surveill."},{"issue":"7898","key":"10.1016\/j.heliyon.2023.e13285_bib51","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"issue":"7901","key":"10.1016\/j.heliyon.2023.e13285_bib52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13285_bib53","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 vaccine against omicron variant in South Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6529","key":"10.1016\/j.heliyon.2023.e13285_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12998\/wjcc.v10.i1.1","article-title":"Omicron variant (B. 1.1. 529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance","volume":"10","author":"Ren","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.heliyon.2023.e13285_bib56","series-title":"SARS-CoV-2 Transmission Dynamics in South Africa and Epidemiological Characteristics of the Omicron Variant","author":"Yang","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib57","series-title":"Variants of Concern and Variants of Interest","author":"Sars-CoV","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib58","series-title":"SARS-CoV-2 Omicron VOC Transmission in Danish Households","author":"Lyngse","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib59","article-title":"SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection","volume":"3","author":"Cele","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.heliyon.2023.e13285_bib60","doi-asserted-by":"crossref","unstructured":"Jassat W., Karim S.A., Mudara C., Welch R., Ozougwu L., Groome M., Govender N., von Gottberg A., Wolter N., Blumberg L., DATCOV author and blumberg, lucille and cohen, C., clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave, Preprint with The Lancet (2021) December 29, 2021.","DOI":"10.2139\/ssrn.3996320"},{"key":"10.1016\/j.heliyon.2023.e13285_bib61","series-title":"SARS-CoV-2 Omicron Variant Replication in Human Respiratory Tract Ex Vivo","author":"Chan","year":"2021"},{"issue":"19","key":"10.1016\/j.heliyon.2023.e13285_bib63","doi-asserted-by":"crossref","first-page":"e00861","DOI":"10.1128\/JVI.00861-21","article-title":"Structural basis of covalent inhibitory mechanism of TMPRSS2-related serine proteases by camostat","volume":"95","author":"Sun","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2023.e13285_bib64","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1021\/acs.jcim.1c01561","article-title":"Transmembrane protease serine 2 proteolytic cleavage of the SARS-CoV-2 spike protein: a mechanistic quantum mechanics\/molecular mechanics study to inspire the design of new drugs to fight the COVID-19 pandemic","volume":"62","author":"Teixeira","year":"2022","journal-title":"J. Chem. Inf. Model."},{"issue":"23","key":"10.1016\/j.heliyon.2023.e13285_bib65","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106267","article-title":"Syncytia formation by SARS\u2010CoV\u20102\u2010infected cells","volume":"39","author":"Buchrieser","year":"2020","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib66","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3201\/eid2802.212422","article-title":"Probable transmission of SARS-CoV-2 omicron variant in quarantine hotel, Hong Kong, China, November 2021","volume":"28","author":"Gu","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.heliyon.2023.e13285_bib67","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jmv.27528","article-title":"The electrostatic potential of the Omicron variant spike is higher than in Delta and Delta-plus variants: a hint to higher transmissibility?","volume":"94","author":"Pascarella","year":"2022","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib68","first-page":"263","article-title":"SARS-CoV-2 variant Omicron (B. 1.1. 529) is in a rising trend of mutations increasing the positive electric charge in crucial regions of the spike protein S","volume":"69","author":"Paw\u0142owski","year":"2022","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.heliyon.2023.e13285_bib69","series-title":"Omicron: Understanding the Latest Variant of SARS\u2010CoV\u20102 and Strategies for Tackling the Infection","author":"Obireddy","year":"2022"},{"issue":"19","key":"10.1016\/j.heliyon.2023.e13285_bib70","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13285_bib71","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.heliyon.2023.e13285_bib72","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10277","key":"10.1016\/j.heliyon.2023.e13285_bib73","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(21)00528-6","article-title":"Single-dose Oxford\u2013AstraZeneca COVID-19 vaccine followed by a 12-week booster","volume":"397","author":"Hung","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e13285_bib74","series-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","author":"Polack","year":"2020"},{"issue":"10269","key":"10.1016\/j.heliyon.2023.e13285_bib75","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","article-title":"Oxford\u2013AstraZeneca COVID-19 vaccine efficacy","volume":"397","author":"Knoll","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e13285_bib76","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13285_bib77","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.pedhc.2021.04.001","article-title":"Methodological analysis: randomized controlled trials for pfizer and Moderna COVID-19 vaccines","volume":"35","author":"Hallas","year":"2021","journal-title":"J. Pediatr. Health Care"},{"key":"10.1016\/j.heliyon.2023.e13285_bib78","first-page":"1663","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","author":"Meo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"15","key":"10.1016\/j.heliyon.2023.e13285_bib79","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.2021.2927","article-title":"The Johnson & Johnson vaccine for COVID-19","volume":"325","author":"Livingston","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2023.e13285_bib80","volume":"vol. 373","author":"Bernal","year":"2021"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e13285_bib81","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/clinchem\/48.10.1647","article-title":"Stability of endogenous and added RNA in blood specimens, serum, and plasma","volume":"48","author":"Tsui","year":"2002","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib82","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4161\/hv.4.1.4747","article-title":"Evidence based route of administration of vaccines","volume":"4","author":"Cook","year":"2008","journal-title":"Hum. Vaccine"},{"issue":"13","key":"10.1016\/j.heliyon.2023.e13285_bib83","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.vaccine.2005.11.057","article-title":"Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults","volume":"24","author":"Cook","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib84","first-page":"1","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vacc."},{"key":"10.1016\/j.heliyon.2023.e13285_bib85","series-title":"There Are Millions of Protein Factories in Every Cell. Surprise, They\u2019re Not All the Same","author":"Leslie","year":"2017"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib86","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/tra.12026","article-title":"Presentation of phagocytosed antigens by MHC class I and II","volume":"14","author":"Mantegazza","year":"2013","journal-title":"Traffic"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13285_bib87","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class I and MHC class II antigen presentation","volume":"11","author":"Neefjes","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2023.e13285_bib88","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fimmu.2014.00182","article-title":"Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines","volume":"5","author":"van Montfoort","year":"2014","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13285_bib89","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2567.2007.02719.x","article-title":"Immunological decision\u2010making: how does the immune system decide to mount a helper T\u2010cell response?","volume":"123","author":"Kaiko","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.heliyon.2023.e13285_bib90","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fimmu.2019.01234","article-title":"On analyzing how the Th1\/Th2 phenotype of an immune response is determined: classical observations must not be ignored","volume":"10","author":"Bretscher","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13285_bib91","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/sji.12175","article-title":"On the mechanism determining the TH1\/TH2 phenotype of an immune response, and its pertinence to strategies for the prevention, and treatment, of certain infectious diseases","volume":"79","author":"Bretscher","year":"2014","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.heliyon.2023.e13285_bib92","article-title":"Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection","author":"Nemet","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e13285_bib93","article-title":"Plasma neutralization of the SARS-CoV-2 omicron variant","author":"Schmidt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e13285_bib94","series-title":"Early Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with COVID-19 Caused by the Omicron Variant of SARS-CoV-2 in Houston","first-page":"2021","author":"Christensen","year":"2022"},{"key":"10.1016\/j.heliyon.2023.e13285_bib95","series-title":"Clinical Outcomes Among Patients Infected with Omicron (B. 1.1. 529) SARS-CoV-2 Variant in Southern California","author":"Lewnard","year":"2022"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib96","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat. Immunol."},{"issue":"10224","key":"10.1016\/j.heliyon.2023.e13285_bib97","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e13285_bib98","series-title":"Poliomyelitis Key Facts: World Health Organization","author":"Organization","year":"2019"},{"key":"10.1016\/j.heliyon.2023.e13285_bib99","series-title":"Measles Key Facts","author":"Organization","year":"2019"},{"key":"10.1016\/j.heliyon.2023.e13285_bib100","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jped.2020.09.002","article-title":"Genetics of COVID-19","volume":"97","author":"Raskin","year":"2021","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13285_bib101","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jmv.27526","article-title":"Omicron and Delta variant of SARS\u2010CoV\u20102: a comparative computational study of spike protein","volume":"94","author":"Kumar","year":"2021","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13285_bib102","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1110\/ps.073347208","article-title":"The epitope space of the human proteome","volume":"17","author":"Berglund","year":"2008","journal-title":"Protein Sci."},{"key":"10.1016\/j.heliyon.2023.e13285_bib103","first-page":"1","article-title":"Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario","author":"Nasreen","year":"2022","journal-title":"Nat. Microb."},{"issue":"16","key":"10.1016\/j.heliyon.2023.e13285_bib104","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e13285_bib105","series-title":"Duration of Protection of BNT162b2 and mRNA-1273 COVID-19 Vaccines against Symptomatic SARS-CoV-2 Omicron Infection in Qatar","author":"Chemaitelly","year":"2022"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13285_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004037","article-title":"Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: a Danish nationwide study","volume":"19","author":"Nielsen","year":"2022","journal-title":"PLoS Med."},{"key":"10.1016\/j.heliyon.2023.e13285_bib107","series-title":"Protection against Omicron (B. 1.1. 529) BA. 2 Reinfection Conferred by Primary Omicron BA. 1 or Pre-omicron SARS-CoV-2 Infection Among Health-Care Workers with and without mRNA Vaccination: a Test-Negative Case-Control Study","author":"Carazo","year":"2022"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib108","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic omicron infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e13285_bib109","first-page":"1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e13285_bib110","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2119236","article-title":"SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons","author":"R\u00f6ssler","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e13285_bib111","series-title":"mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity against SARS-CoV-2 Omicron Variant","author":"Garcia-Beltran","year":"2022"},{"key":"10.1016\/j.heliyon.2023.e13285_bib112","author":"Thompson","year":"2022"},{"key":"10.1016\/j.heliyon.2023.e13285_bib113","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jinf.2021.12.044","article-title":"Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups","volume":"84","author":"Whitaker","year":"2022","journal-title":"J. Infect."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.720","article-title":"Vaccine-breakthrough infection by the SARS-CoV-2 omicron variant elicits broadly cross-reactive immune responses","volume":"12","author":"Zhou","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"6508","key":"10.1016\/j.heliyon.2023.e13285_bib115","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8511","article-title":"Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications","volume":"369","author":"Mathew","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2023.e13285_bib116","series-title":"Booster Protects against Omicron","author":"Pfizer","year":"2021"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib117","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/v14010079","article-title":"SARS-CoV-2 T cell responses elicited by COVID-19 vaccines or infection are expected to remain robust against omicron","volume":"14","author":"Ahmed","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2023.e13285_bib118","series-title":"SARS-CoV-2 Spike T Cell Responses Induced upon Vaccination or Infection Remain Robust against Omicron","author":"Keeton","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib119","series-title":"Divergent SARS CoV-2 Omicron-specific T-And B-Cell Responses in COVID-19 Vaccine Recipients","author":"GeurtsvanKessel","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib120","series-title":"Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant","author":"Liu","year":"2022"},{"key":"10.1016\/j.heliyon.2023.e13285_bib121","first-page":"2235","article-title":"The vaccine efficacy against the SARS-CoV-2 omicron: a systemic review and meta-analysis","author":"Zou","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.heliyon.2023.e13285_bib122","article-title":"COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence\u201425 US Jurisdictions","volume":"71","author":"Johnson","year":"2022","journal-title":"MMWR (Morb. Mortal. Wkly. Rep.)"},{"issue":"15","key":"10.1016\/j.heliyon.2023.e13285_bib123","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/jama.2021.4367","article-title":"CDC interim recommendations for fully vaccinated people: an important first step","volume":"325","author":"Christie","year":"2021","journal-title":"JAMA"},{"issue":"7594","key":"10.1016\/j.heliyon.2023.e13285_bib124","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"issue":"396","key":"10.1016\/j.heliyon.2023.e13285_bib127","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e13285_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib129","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"issue":"15","key":"10.1016\/j.heliyon.2023.e13285_bib130","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13285_bib131","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"19","key":"10.1016\/j.heliyon.2023.e13285_bib132","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19: final report","volume":"383","author":"Group","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.heliyon.2023.e13285_bib133","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e13285_bib134","article-title":"Early remdesivir to prevent progression to severe covid-19 in outpatients","author":"Gottlieb","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.heliyon.2023.e13285_bib135","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMp2032369","article-title":"FDA approval of remdesivir\u2014a step in the right direction","volume":"383","author":"Rubin","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13285_bib136","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19\u2014interim WHO solidarity trial results","volume":"384","author":"Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e13285_bib137","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","author":"Jayk Bernal","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"541","key":"10.1016\/j.heliyon.2023.e13285_bib138","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"24","key":"10.1016\/j.heliyon.2023.e13285_bib139","doi-asserted-by":"crossref","first-page":"e01348","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral \u03b2-d-N 4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e13285_bib140","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"7850","key":"10.1016\/j.heliyon.2023.e13285_bib141","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib142","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nature microbiology"},{"key":"10.1016\/j.heliyon.2023.e13285_bib143","series-title":"Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-To-Moderate COVID-19","author":"Merck","year":"2021"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13285_bib144","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1073\/pnas.111085598","article-title":"RNA virus error catastrophe: direct molecular test by using ribavirin","volume":"98","author":"Crotty","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.heliyon.2023.e13285_bib145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.trsl.2019.12.002","article-title":"Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model","volume":"218","author":"Toots","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/j.heliyon.2023.e13285_bib146","series-title":"Remdesivir, Molnupiravir and Nirmatrelvir Remain Active against SARS-CoV-2 Omicron and Other Variants of Concern","author":"Vangeel","year":"2022"},{"key":"10.1016\/j.heliyon.2023.e13285_bib147","series-title":"Covid-19: Molnupiravir Reduces Risk of Hospital Admission or Death by 50% in Patients at Risk, MSD Reports","author":"Mahase","year":"2021"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib148","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/antibiotics11020220","article-title":"Oral nirmatrelvir\/ritonavir therapy for COVID-19: the dawn in the dark?","volume":"11","author":"Hung","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.heliyon.2023.e13285_bib149","series-title":"A Tale of Two Antiviral Targets-And the COVID-19 Drugs that Bind Them, Nature Reviews","author":"Cully","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128629","article-title":"Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir","volume":"62","author":"Ullrich","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.heliyon.2023.e13285_bib151","series-title":"Covid-19: Pfizer's Paxlovid Is 89% Effective in Patients at Risk of Serious Illness, Company Reports","author":"Mahase","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib152","doi-asserted-by":"crossref","first-page":"980002","DOI":"10.3389\/fmed.2022.980002","article-title":"The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: results of a non-randomized clinical trial","volume":"9","author":"Zhong","year":"2022","journal-title":"Front. Med."},{"issue":"28","key":"10.1016\/j.heliyon.2023.e13285_bib153","doi-asserted-by":"crossref","first-page":"E969","DOI":"10.1503\/cmaj.220471","article-title":"Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis","volume":"194","author":"Pitre","year":"2022","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.heliyon.2023.e13285_bib154","series-title":"Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332\/Ritonavir in Healthy Participants","author":"archive","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib155","series-title":"Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted with Ritonavir","author":"archive","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib156","series-title":"Study of PF-07321332 in Healthy Participants","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib157","volume":"vol. 19","year":"2021"},{"issue":"6575","key":"10.1016\/j.heliyon.2023.e13285_bib158","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13285_bib159","doi-asserted-by":"crossref","first-page":"e2133090","DOI":"10.1001\/jamanetworkopen.2021.33090","article-title":"Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants","volume":"4","author":"Oskotsky","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.heliyon.2023.e13285_bib160","series-title":"SARS-CoV-2 Infection and Oxidative Stress: Pathophysiological Insight into Thrombosis and Therapeutic Opportunities","author":"Alam","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e13285_bib161","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3389\/fnins.2019.00733","article-title":"The sigma-1 receptor in cellular stress signaling","volume":"13","author":"Hayashi","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.heliyon.2023.e13285_bib162","first-page":"1","article-title":"Mechanisms of action of fluvoxamine for COVID-19: a historical review","author":"Hashimoto","year":"2022","journal-title":"Mol. Psychiatr."},{"issue":"478","key":"10.1016\/j.heliyon.2023.e13285_bib163","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5266","article-title":"Modulation of the sigma-1 receptor\u2013IRE1 pathway is beneficial in preclinical models of inflammation and sepsis","volume":"11","author":"Rosen","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e13285_bib164","first-page":"763","article-title":"Fluvoxamine: a review of its mechanism of action and its role in COVID-19","author":"Sukhatme","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106044","article-title":"Widely available lysosome targeting agents should be considered as potential therapy for COVID-19","volume":"56","author":"Homolak","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"22","key":"10.1016\/j.heliyon.2023.e13285_bib166","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2023.e13285_bib167","series-title":"Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19, Open Forum Infectious Diseases","author":"Seftel","year":"2021"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e13285_bib168","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1038\/s41380-021-01021-4","article-title":"Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study","volume":"26","author":"Hoertel","year":"2021","journal-title":"Mol. Psychiatr."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib169","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial","volume":"10","author":"Reis","year":"2022","journal-title":"Lancet Global Health"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00406-021-01326-z","article-title":"Old drug fluvoxamine, new hope for COVID-19","volume":"272","author":"Hashimoto","year":"2022","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib171","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19\uff1a a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib172","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087140","article-title":"Tempol, an intracellular antioxidant, inhibits tissue factor expression, attenuates dendritic cell function, and is partially protective in a murine model of cerebral malaria","volume":"9","author":"Francischetti","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib173","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2010.01.003","article-title":"Effects of tempol and redox-cycling nitroxides in models of oxidative stress","volume":"126","author":"Wilcox","year":"2010","journal-title":"Pharmacol. Therapeut."},{"issue":"5\u20136","key":"10.1016\/j.heliyon.2023.e13285_bib174","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000073600","article-title":"Oxidative stress in endothelial cell dysfunction and thrombosis","volume":"32","author":"Loscalzo","year":"2002","journal-title":"Pathophysiol. Haemostasis Thrombosis"},{"key":"10.1016\/j.heliyon.2023.e13285_bib175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40635-015-0057-y","article-title":"Scavenging reactive oxygen species using tempol in the acute phase of renal ischemia\/reperfusion and its effects on kidney oxygenation and nitric oxide levels","volume":"3","author":"Aksu","year":"2015","journal-title":"Intens. care Med. Exper."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13285_bib177","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1248\/bpb.28.641","article-title":"Tempol protects against ischemic acute renal failure by inhibiting renal noradrenaline overflow and endothelin-1 overproduction","volume":"28","author":"Fujii","year":"2005","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib178","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1523-1755.2000.00212.x","article-title":"Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat","volume":"58","author":"Chatterjee","year":"2000","journal-title":"Kidney Int."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13285_bib179","first-page":"1238","article-title":"Tempol relieves lung injury in a rat model of chronic intermittent hypoxia via suppression of inflammation and oxidative stress","volume":"21","author":"Wang","year":"2018","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.heliyon.2023.e13285_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108828","article-title":"Brief report: tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients","volume":"231","author":"Mathi","year":"2021","journal-title":"Clin. Immunol."},{"issue":"6551","key":"10.1016\/j.heliyon.2023.e13285_bib181","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1126\/science.abi5224","article-title":"Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets","volume":"373","author":"Maio","year":"2021","journal-title":"Science"},{"issue":"33","key":"10.1016\/j.heliyon.2023.e13285_bib182","doi-asserted-by":"crossref","first-page":"12028","DOI":"10.1073\/pnas.0805361105","article-title":"Tempol-mediated activation of latent iron regulatory protein activity prevents symptoms of neurodegenerative disease in IRP2 knockout mice","volume":"105","author":"Ghosh","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13285_bib183","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1172\/JCI97684","article-title":"Translational repression of HIF2\u03b1 expression in mice with Chuvash polycythemia reverses polycythemia","volume":"128","author":"Ghosh","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2023.e13285_bib184","series-title":"Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients","author":"gov ClinicalTrials","year":"2021"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-53864-1","article-title":"Disassociation of vitamin D's calcemic activity and non-calcemic genomic activity and individual responsiveness: a randomized controlled double-blind clinical trial","volume":"9","author":"Shirvani","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13285_bib186","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.heliyon.2023.e13285_bib187","article-title":"The role of vitamin D in reducing SARS-CoV-2 infection: an update","volume":"97","author":"Alam","year":"2021","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2023.e13285_bib188","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/postgradmedj-2020-139065","article-title":"Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)","volume":"98","author":"Rastogi","year":"2022","journal-title":"Postgrad. Med."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13285_bib189","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.3390\/nu12113377","article-title":"Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: the GERIA-COVID quasi-experimental study","volume":"12","author":"Annweiler","year":"2020","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13285_bib190","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2020.26848","article-title":"Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial","volume":"325","author":"Murai","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13285_bib191","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/07315724.2020.1850371","article-title":"l-Cysteine stimulates the effect of vitamin D on inhibition of oxidative stress, IL-8, and MCP-1 secretion in high glucose treated monocytes","volume":"40","author":"Jain","year":"2021","journal-title":"J. Am. Coll. Nutr."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13285_bib192","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/nu12010236","article-title":"A review of micronutrients and the immune system\u2013working in harmony to reduce the risk of infection","volume":"12","author":"Gombart","year":"2020","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13285_bib193","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/ajcn\/nqy274","article-title":"Magnesium status and supplementation influence vitamin D status and metabolism: results from a randomized trial","volume":"108","author":"Dai","year":"2018","journal-title":"Am. J. Clin. Nutr."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13285_bib194","first-page":"3418","article-title":"Panel on Dietetic Products, Allergies, Scientific opinion on dietary reference values for vitamin C","volume":"11","author":"Efsa","year":"2013","journal-title":"EFSA J."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13285_bib195","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.pathol.2018.07.004","article-title":"Vitamin C deficiency in an Australian cohort of metropolitan surgical patients","volume":"50","author":"Ravindran","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.heliyon.2023.e13285_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100064","article-title":"Serum levels of vitamin C and vitamin D in a cohort of critically ill COVID-19 patients of a north American community hospital intensive care unit in May 2020: a pilot study","volume":"8","author":"Arvinte","year":"2020","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.heliyon.2023.e13285_bib197","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13613-020-00792-3","article-title":"High-dose Vitamin C Infusion for the Treatment of Critically Ill COVID-19","volume":"11","author":"Zhang","year":"2021","journal-title":"Ann. Intensive Care"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib198","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/14787210.2020.1706483","article-title":"The antiviral properties of vitamin C","volume":"18","author":"Colunga Biancatelli","year":"2020","journal-title":"Expert Rev. Anti-infect. Ther."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13285_bib199","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib200","doi-asserted-by":"crossref","first-page":"G241","DOI":"10.1152\/ajpgi.00071.2018","article-title":"Tumor necrosis factor alpha reduces intestinal vitamin C uptake: a role for NF-\u03baB-mediated signaling","volume":"315","author":"Subramanian","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e13285_bib201","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.3390\/nu5083131","article-title":"Vitamin C: a novel regulator of neutrophil extracellular trap formation","volume":"5","author":"Mohammed","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.heliyon.2023.e13285_bib202","doi-asserted-by":"crossref","first-page":"426740","DOI":"10.1155\/2014\/426740","article-title":"Vitamin C mitigates oxidative stress and tumor necrosis factor-alpha in severe community-acquired pneumonia and LPS-induced macrophages","volume":"2014","author":"Chen","year":"2014","journal-title":"Mediat. Inflamm."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13285_bib203","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/nu12020292","article-title":"The emerging role of vitamin C as a treatment for sepsis","volume":"12","author":"Kashiouris","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.heliyon.2023.e13285_bib204","doi-asserted-by":"crossref","first-page":"L20","DOI":"10.1152\/ajplung.00300.2011","article-title":"Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid","volume":"303","author":"Fisher","year":"2012","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.heliyon.2023.e13285_bib205","article-title":"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study","volume":"203","author":"Castillo","year":"2020","journal-title":"J. Steroid Biochem. Mol. Biol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023004929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023004929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:58:23Z","timestamp":1776877103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023004929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":203,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2405844023004929"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e13285","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e13285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e13285"}}